with their burden often extending to longer-term complications such as event recurrence and post-thrombotic syndrome (PTS). Few data exist on the overall economic burden of DVT and PE and their ...

Meanwhile, continuous renal replacement therapy, plasma exchange, and immunoglobulin infusion were performed, and rituximab was tried (2 × 500 mg intravenous infusions, each separated by 15 days) to ...

No safety concerns emerged in part one of the phase 1 trial assessing CS014, a histone deacetylase inhibitor that has ...

Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the first participant ...

As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in ...

Researchers used feedback from patient focus groups to develop tools and recommendations for shared anticoagulant ...

Contemporary estrogen-progestin contraceptives are associated with an increased risk for ischemic stroke and myocardial infarction.

In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...

Solid Biosciences reported recent positive data in developing their gene therapy candidate SGT-003. The phase 1/2 INSPIRE ...

Thrombosis is also the major initiating factor in unstable angina, particularly when rest pain is recent and increasing in severity. Necropsy studies suggest that a new thrombotic coronary event ...

Omeros Corporation's stock surges as narsoplimab data shows 68% lower death risk in HSCT-TMA patients. Click to learn about the potential and risks of OMER stock.

Since the advent of drug-eluting stents, there has been a debate in the intervention community over how long dual ...